Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dimeric naphthoquinone 3** is a naturally occurring small molecule isolated from the roots of *Diospyros lotus*. It is a dimeric naphthoquinone, specifically characterized as 8,5′,8′-trihydroxy-6,6′-dimethyl-7,3′-binaphthyl-1,4,1′,4′-tetraone. This compound exhibits **antiproliferative and cytotoxic effects** on mouse T-cell lymphoma cell lines, both parental and multidrug-resistant (MDR) variants, with notable activity against P-glycoprotein (ABCB1)–mediated MDR. The mechanism of action includes reversal of MDR and induction of cytotoxicity, likely via modulation of *P*-glycoprotein and apoptosis induction. It is part of a class of naphthoquinone dimers actively researched for their anticancer potential, especially as MDR modulators[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimeric naphthoquinone 3.